Sanofi to Acquire Blueprint Medicines
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology.
immunology
US Merck Snaps up Prometheus Biosciences for $10.8 Billion
Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.
Bayer Plans to Scale Back Women’s Health R&D
Ahead of a change in leadership at the top after the upcoming annual general meeting, in interviews with news agencies Bayer is dropping hints in dribbles about future plans for its healthcare business.
Pfizer Doubles Dublin Biologicals Capacity
Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.
